Resolve Therapeutics Raises $5.8 Million in Private Financing

  Resolve Therapeutics Raises $5.8 Million in Private Financing

     Proceeds Will Support 2013 Clinical Trial of Lupus Compound RSLV-132

Business Wire

SEATTLE -- November 01, 2012

Resolve Therapeutics, LLC today announced that the company has raised $5.8
million in a Series B private-equity financing. The financing was led by
previous investor New Science Ventures, with the participation of new investor
WRF Capital (venture investment arm of Washington Research Foundation) and
previous investor Easton Capital.

“These funds give Resolve the necessary resources to advance our
investigational lupus compound RSLV-132 into clinical trials, which we expect
to start in mid-2013,” said James Posada, Ph.D., Chief Executive Officer of
Resolve. “We are excited about this novel new approach to treating lupus,
which eliminates the immune complexes that represent one of the central causes
of the disease. More importantly, the leading pharmaceutical companies are
excited by it as well, which portends a bright future for Resolve.”

“Resolve’s therapeutic approach and capital-efficient development model
provide a unique and compelling investment opportunity for WRF Capital,” said
Thong Q. Le, Managing Director at WRF Capital. “We are pleased to join New
Science Ventures and Easton Capital to support the continued development of
Resolve’s lead program RSLV-132.”

“Resolve has made significant progress in the development of RSLV-132, from
the company’s formation around an academic concept developed at the University
of Washington in early 2010 to the creation of a clinical candidate currently
completing IND-enabling studies,” said Somu Subramaniam, Founder and Managing
Partner of New Science Ventures. “To have achieved this accomplishment on
total funding of less than $3 million to date is strong validation of
Resolve’s business model for capital-efficient drug development.”

About New Science Ventures

New Science Ventures (NSV) is a New York-based venture capital firm which
invests in both early and late stage companies using novel scientific
approaches to address significant unmet needs and create order of magnitude
improvements in performance. NSV manages over $150 million and has invested in
more than 20 companies located in the US, Europe, India and China in the life
sciences and information technology sectors.

About WRF Capital

WRF Capital is the venture investment arm of the Washington Research
Foundation, an independent organization founded in 1981 to support research
and scholarship at Washington state research institutions. A leading
early-stage investor, WRF Capital partners with entrepreneurs, investors,
local universities, and research institutions to develop market-leading
technology companies. Proceeds from investments are used to make financial
gifts to Washington State research institutions to support scholarship and
research. Examples of WRF Capital's life science companies include
Accelerator, Alder Biopharmaceuticals, Amnis (acquired by EMD Millipore),
Cardeas Pharma, Corus Pharma (acquired by Gilead Sciences), Ekos, GlobeImmune,
HaloSource (LSE: HALO.L), Hyperion Therapeutics (NASDAQ: HPTX), Ikaria, Lumera
(Nasdaq^NM: LMRA), Mirador Biomedical, Omeros (NASDAQ: OMER), Pathway Medical
Technologies (acquired by MEDRAD), Targeted Growth, VLST, and Uptake Medical.
For more information, visit http://www.wrfcapital.com.

About Easton Capital

Easton Capital Investment Group  manages approximately $200 million in several
funds. Easton focuses on capital efficient paradigm shifting technologies in
the life sciences that address fundamental needs. The firm is stage agnostic
and invests primarily in the biotechnology, medical device and diagnostic
sectors, though it has also backed service businesses in the past. Its
investments have ranged in size from $1 million to $8.5 million. Easton has
offices in New York and Florida.

About Resolve Therapeutics

Resolve Therapeutics is a privately held biotechnology company based in
Seattle that is dedicated to helping patients with lupus through the
development of RSLV-132, its novel targeted biologic therapy. RSLV-132
represents a new approach to inhibiting the production of interferon-alpha at
a proximal step in the inflammatory cascade. A multitude of evidence points to
interferon-alpha as a critical mediator of the inflammation present in lupus
patients. Development efforts in this field are greatly enhanced by the recent
clinical validation of a biomarker called the “interferon signature” which
tracks the activation level of the interferon pathway in lupus patients. The
interferon signature provides a valuable pharmacodynamic endpoint which
greatly enhances the early clinical evaluation of drugs acting to inhibit the
interferon pathway. RSLV-132 is currently in advanced preclinical development,
and Resolve expects to begin human clinical studies with this compound in the
near future. For more information please visit the Resolve Therapeutics
website at http://www.resolvebio.com.

Contact:

Resolve Therapeutics, LLC
James Posada, Ph.D., MBA, 208-876-4057
CEO
or
Kureczka/Martin Associates
Joan Kureczka, 415-821-2413
Joan@kureczka-martin.com